You can buy or sell CSII and other stocks, options, ETFs, and crypto commission-free!
Cardiovascular Systems, Inc. Common Stock, also called Cardiovascular Systems, is a medical device company, which engages in the development and commercialization of solutions for treating vascular and coronary disease. Read More It offers orbital atherectomy systems for both peripheral and coronary commercial applications. Its products are catheter-based platforms capable of treating a range of vessel sizes and plaque types. The company was founded in 2000 and is headquartered in St. Paul, MN.
St. Paul, Minnesota
52 Week High
52 Week Low
Cardiovascular Systems (CSII) Q3 Earnings Top, View Tapered
Cardiovascular Systems, Inc. CSII delivered earnings per share of 2 cents in third-quarter fiscal 2019 compared with the year-ago earnings of a penny. The reported figure beat the Zacks Consensus Estimate of a loss of 4 cents. Net Sales Cardiovascular Systems' revenues of $63.3 million in the fiscal third quarter marks a 13.9% year-over-year increase. Meanwhile, the top line matched the Zacks Consensus Estimate. Segment Details Coronary device revenues jumped above 24% year over year to $18.2 million. ...
Seeking AlphaMay 1
Cardiovascular Systems' (CSII) CEO Scott Ward on Q3 2019 Results - Earnings Call Transcript
Cardiovascular Systems, Inc. (NASDAQ:CSII) Q3 2019 Earnings Conference Call May 1, 2019 4:30 PM ET Company Participants Jack Nielsen – Vice President, Investor Relations and Corporate Communications Scott Ward – Chairman, President and Chief Executive Officer Jeff Points – Chief Financial Officer Rhonda Robb – Chief Operating Officer Conference Call Participants Mathew Blackman – Stifel Danielle Antalffy – SVB Leerink David Saxon – Needham & Company Brooks O’Neil – Lake Street Capital Brandon Vaz...
Yahoo FinanceMay 1
Cardiovascular Systems, Inc. Reports Fiscal 2019 Third-Quarter Financial Results
ST. PAUL, Minn.--(BUSINESS WIRE)-- Conference Call Scheduled for Today, May 1, 2019, at 3:30 PM CT (4:30 PM ET) Cardiovascular Systems, Inc. (CSI®) (CSII), a medical device company developing and commercializing innovative interventional treatment systems for patients with peripheral and coronary artery disease, today reported financial results for its fiscal third quarter, ended March 31, 2019. CSI’s third-quarter revenues were $63.3 million, an increase of $7.7 million, or 13.9%, from the third quarter...
Expected Jul 31, After Hours